Currently Browsing: FDA

Read More

New ACRO Report Quantifies Benefits of RBM for Quality Reviews

October 17, 2019

A new report based on a survey of ACRO members reveals that Risk-Based Monitoring (RBM) makes clinical trial quality review more efficient…

Read More

Advancing the Adoption of Risk-Based Monitoring Strategies in Clinical Trials

August 16, 2019

On July 17, 2019, under cooperative agreement with the FDA, the Duke-Margolis Center for Health Policy (Duke Margolis) held a public workshop. The event, titled Improving the Implementation of Risk-Based Monitoring Approaches of Clinical Investigations, aimed to identify opportunities to improve Risk Based Monitoring (RBM) implementation and solicit stakeholder input on the challenges, barriers, and enablers that impact the successful adoption of RBM.

Read More
NewsPress Releases

ACRO offers unique insights on risk-based monitoring of clinical trials, calls for adoption of RBM as a best practice

May 16, 2019

Following meetings with then-Commissioner Scott Gottlieb and senior leadership from the Center for Drug Evaluation and Research on the role of CROs and technology companies in designing and implementing risk-based monitoring (RBM) of clinical trials, ACRO this week submitted extensive comments on recent FDA Guidance.Increasing the use of innovative RBM technologies helps make clinical trials safer, more efficient and higher quality. ACRO’s comments offer unique insights into the recent expansion of RBM implementation and call for further increasing the use of these oversight technologies.

Read More

Who’s in and who’s out? ACRO talks Inclusion-Exclusion Criteria

May 29, 2018

ACRO joins FDA public meeting to discuss trial risks and rationale, benefits and barriers Clinical trials have an enormous number of inter-related,…